CIMZIA certolizumab pegol (rbe) 200 mg/mL solution for injection Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cimzia certolizumab pegol (rbe) 200 mg/ml solution for injection

ucb australia pty ltd t/a ucb pharma division of ucb australia - certolizumab pegol, quantity: 200 mg - injection, solution - excipient ingredients: sodium acetate; sodium chloride; water for injections - rheumatoid arthritis cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients. ? combined with mtx in case of either an inadequate response or intolerance to previous therapy with one or more disease modifying antirheumatic drugs (dmards) or ? as monotherapy in case of a contraindication or intolerance to mtx (see section 4.2 dose and method of administration). cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray, when given in combination with mtx. cimzia in combination with mtx is indicated for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with mtx or other dmards.,psoriatic arthritis cimzia is indicated for the treatment of adult patients with active psoriatic arthritis where response to previous disease modifying antirheumatic drug therapy (dmards) has been inadequate. cimzia has been shown to improve physical function.,ankylosing spondylitis cimzia is indic

CIMZIA certolizumab pegol (rbe) 200 mg/mL solution for Injection Australia - engelsk - Department of Health (Therapeutic Goods Administration)

cimzia certolizumab pegol (rbe) 200 mg/ml solution for injection

ucb australia pty ltd t/a ucb pharma division of ucb australia - certolizumab pegol, quantity: 200 mg - injection, solution - excipient ingredients: sodium acetate; sodium chloride; water for injections - rheumatoid arthritis cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients. ? combined with mtx in case of either an inadequate response or intolerance to previous therapy with one or more disease modifying antirheumatic drugs (dmards) or ? as monotherapy in case of a contraindication or intolerance to mtx (see section 4.2 dose and method of administration). cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray, when given in combination with mtx. cimzia in combination with mtx is indicated for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with mtx or other dmards. psoriatic arthritis cimzia is indicated for the treatment of adult patients with active psoriatic arthritis where response to previous disease modifying antirheumatic drug therapy (dmards) has been inadequate. cimzia has been shown to improve physical function.,ankylosing spondylitis cimzia is indic

CIMZIA- certolizumab pegol kit
CIMZIA- certolizumab pegol injection, solution USA - engelsk - NLM (National Library of Medicine)

cimzia- certolizumab pegol kit cimzia- certolizumab pegol injection, solution

ucb, inc. - certolizumab pegol (unii: umd07x179e) (certolizumab pegol - unii:umd07x179e) - certolizumab pegol 200 mg in 1 ml - cimzia is indicated for reducing signs and symptoms of crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. cimzia is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (ra). cimzia is indicated for the treatment of adult patients with active psoriatic arthritis (psa). cimzia is indicated for the treatment of adults with active ankylosing spondylitis (as). [see clinical studies (14.4)] cimzia is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axspa) with objective signs of inflammation [see clinical studies (14.5)]. cimzia is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (pso) who are candidates for systemic therapy or phototherapy [see clinical studies (14.6)] cimzia is con

JIVI damoctocog alfa pegol 1000 IU powder for injection vial with diluent syringe Australia - engelsk - Department of Health (Therapeutic Goods Administration)

jivi damoctocog alfa pegol 1000 iu powder for injection vial with diluent syringe

bayer australia ltd - damoctocog alfa pegol, quantity: 1000 iu - injection, powder for - excipient ingredients: polysorbate 80; calcium chloride dihydrate; glycine; sodium chloride; sucrose; histidine - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

JIVI damoctocog alfa pegol 2000 IU powder for injection vial with diluent syringe Australia - engelsk - Department of Health (Therapeutic Goods Administration)

jivi damoctocog alfa pegol 2000 iu powder for injection vial with diluent syringe

bayer australia ltd - damoctocog alfa pegol, quantity: 2000 iu - injection, powder for - excipient ingredients: glycine; histidine; sucrose; calcium chloride dihydrate; sodium chloride; polysorbate 80 - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

JIVI damoctocog alfa pegol 250 IU powder for injection vial with diluent syringe Australia - engelsk - Department of Health (Therapeutic Goods Administration)

jivi damoctocog alfa pegol 250 iu powder for injection vial with diluent syringe

bayer australia ltd - damoctocog alfa pegol, quantity: 250 iu - injection, powder for - excipient ingredients: polysorbate 80; sucrose; glycine; calcium chloride dihydrate; histidine; sodium chloride - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

JIVI damoctocog alfa pegol 3000 IU powder for injection vial with diluent syringe Australia - engelsk - Department of Health (Therapeutic Goods Administration)

jivi damoctocog alfa pegol 3000 iu powder for injection vial with diluent syringe

bayer australia ltd - damoctocog alfa pegol, quantity: 3000 iu - injection, powder for - excipient ingredients: calcium chloride dihydrate; sucrose; sodium chloride; glycine; histidine; polysorbate 80 - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

JIVI damoctocog alfa pegol 500 IU powder for injection vial with diluent syringe Australia - engelsk - Department of Health (Therapeutic Goods Administration)

jivi damoctocog alfa pegol 500 iu powder for injection vial with diluent syringe

bayer australia ltd - damoctocog alfa pegol, quantity: 500 iu - injection, powder for - excipient ingredients: sucrose; calcium chloride dihydrate; polysorbate 80; glycine; sodium chloride; histidine - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

EVOREL SEQUI Israel - engelsk - Ministry of Health

evorel sequi

j-c health care ltd - estradiol as hemihydrate; estradiol as hemihydrate; norethisterone acetate - patches - estradiol as hemihydrate 3.2 mg; norethisterone acetate 11.2 mg; estradiol as hemihydrate 3.2 mg - estradiol, combinations - estradiol, combinations - hormone replacement therapy for the relief of menopausal symptoms.